| Company name | Overall score* | Revenue in bn RUB | Profit in bn RUB |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
Download
Source
Source
Release date
September 2021
More information
Region
Russia
Survey time period
2020
Supplementary notes
* The source specified the following information about the scoring: "Companies were evaluated according to six criteria using the weighting coefficient method: revenue for 2020 (weight 30%, maximum score - 30), change in revenue for the year (10%), net profit (30%), change in profit for the year (10%), number of drugs registered on the company (10%) and the number of approvals issued to the company to conduct clinical trials (10%). For the final result, points for all parameters are summed up, companies are ranked by their sum. The maximum possible total score is 100."
The study excluded subsidiaries and representations of international companies.
Citation formats
